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Biological activity ofthe receptor for macrophage colony-stimulating factor
in the human endometrial cancer cell line, Ishikawa
S Takeda*, WP Soutter, NJ Dibb and JO White
Institute of Obstetrics and Gynaecology, Royal Postgraduate Medical School, Hammersmith Hospital, London W12 ONN, UK.
Summary Previously we found that the Ishikawa endometrial cancer cell line expresses macrophage colony-
stimulating factor (M-CSF) and c-fms transcripts and that its proliferation is enhanced by the addition of
recombinant M-CSF. This suggested that Ishikawa cells are constitutively stimulated by M-CSF. In support of
this we now show that Ishikawa cells secrete M-CSF and that known stimulators of M-CSF production
increase the amount detected in Ishikawa cell conditioned medium. Using retroviral infections to introduce and
express exogenous c-fms genes in Ishikawa cells we also demonstrate proliferation to be partially inhibited by a
dominant negative, mutant c-fms gene, yet enhanced approximately 3-fold by a normal c-fms gene, under
conditions in which the only source of M-CSF was that produced by the cells. The data provide evidence for
the existence of an active M-CSF/receptor loop in these endometrial cancer cells and suggests the possibility of
such activity in tumours of the endometrium and ovary that aberrantly express M-CSF and fins genes.
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The sex steroid hormones oestradiol and progesterone
regulate the synthesis of locally acting polypeptide growth
factors and their receptors (Pollard, 1991; Giudice, 1994), and
therefore potentially have indirect as well as direct effects
upon uterine growth and differentiation. Macrophage colony-
stimulating factor (M-CSF) was initially demonstrated to be
under sex-steroid hormone control in the mouse uterus and
to be elevated during pregnancy (Pollard et al., 1987; Arceci
et al., 1989) whereas its receptor, encoded by the proto-
oncogene c-fms (Sherr et al., 1985), was expressed in
trophoblast cells (Arceci et al., 1989; Regenstrief and
Rossant, 1989). Subsequently, M-CSF and its receptor have
been suggested as local mediators at the feto-maternal
interface on the basis of their expression in the pregnant
endometrium and trophoblast respectively (Kauma et al.,
1991; Daiter et al., 1992; Pampfer et al., 1992; Jokhi et al.,
1993). The expression of M-CSF and c-fms is not however
restricted to pregnancy as low-level expression of each
transcript has been detected in normal endometrium
(Kauma et al., 1991; Daiter et al., 1992; Pampfer et al., 1992).
The level of expression of M-CSF and c-fms in
endometrial cancer is greater than in normal and benign
tissue specimens; co-expression of M-CSF and c-fms is
frequently observed in endometrial adenocarcinomas and is
correlated with adverse prognostic indicators (Kacinski et al.,
1988; Baiocchi et al., 1991; Leiserowitz et al., 1993). Elevated
serum M-CSF is a feature of endometrial cancer patients and
is suggested to be a circulating tumour marker of neoplastic
disease activity (Kacinski et al., 1990). Such observations
have led these authors to suggest that overexpression of M-
CSF and c-fms contributes to the development and
progression of endometrial cancer. We have previously
reported on the expression of M-CSF and c-fms mRNA in
the human endometrial adenocarcinoma cell line, Ishikawa,
and demonstrated increased cellular proliferation in response
to recombinant human (rh) M-CSF (Croxtall et al., 1992).
We speculated, therefore, that locally produced M-CSF
regulated proliferation of Ishikawa cells through activation
of the M-CSF receptor (M-CSFr) (Croxtall et al., 1992).
Several reports have shown that mutant receptors with
defective tyrosine kinase activity, such as those for epidermal
growth factor (EGF) and M-CSF (Kashles et al., 1991; Reith
et al., 1993), can form inactive heterodimers with normal
receptors expressed in the same cell or tissue. This approach,
together with the demonstration of M-CSF production by
Ishikawa cells, has been used in the present study to generate
evidence of the functional importance of c-fms and M-CSF
expression in endometrial cancer cells. We found that the
expression of a mutant M-CSFr from a retroviral vector
suppressed the proliferation of Ishikawa cells, indicating that
the endogenous normal M-CSFr actively stimulates growth.
Furthermore, the proliferation of Ishikawa cells was
enhanced by the increased expression of the normal M-
CSFr, as a result of retroviral infection. The results strongly
indicate the functional importance of the c-fms and M-CSF
transcripts present in Ishikawa endometrial cancer cells and
suggests that their overexpression in endometrial cancer
compared with normal endometrium may contribute to the
process of malignant transformation.
Materials and methods
Cell culture
Ishikawa cells were maintained in Dulbecco's Modified Eagle
medium/F12 (DMEM/F112, Sigma) containing 10% fetal calf
serum (FCS) (Gibco). Serum-free medium was used for the
assay of cell growth and the production of M-CSF; it
consisted of DMEM/F12 supplemented with insulin
(6.25 jug ml-'), transferrin (6.35 jig ml-1), selenium (6.25 ng
ml-'), bovine serum albumin (1.25 jig ml-') and linoleic acid
(5.35 jg ml-') (ITS), all from Sigma.
Kinase activity offms protein
For in vitro kinase assays a rabbit polyclonal antibody was
used to immunoprecipitate fms proteins from lysates of
Ishikawa cells (5 x 10-6 cells grown to near confluence in
DMEM/F12+5% FCS). The fms proteins were labelled with
y-ATP in vitro and analysed by SDS-PAGE as previously
described (Dibb et al., 1990).
Determination of M-CSF in conditioned medium
The immunological detection of M-CSF was accomplished by
dot-blot assay of serum-free culture medium conditioned by
Ishikawa cells following treatment with tumour necrosis
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factor a (TNF-oc) (1, 2.5 and 5 ng ml-'), 8-bromo cAMP (5,
7.5 and 10 mM) or phorbol 12-myristate 13-acetate (TPA, 0.5
and 1 mM) for 24 h. Media were blotted onto zeta-probe
membrane (Bio-Rad) by microfiltration, blocked in 5% milk
powder solution, washed and incubated with rabbit antihu-
man M-CSF polyclonal antibody at a final dilution of 1:7500
(Genzyme Corporation). The immunoblots were visualised
using alkaline phosphatase (Bio-Rad) according to the
manufacturer's specifications. In preliminary experiments
this procedure detected rhM-CSF but not IL-I1,, IL-2,
granulocyte colony-stimulating factor (G-CSF) or granulo-
cyte-macrophage colony-stimulating factor (GM-CSF).
Infection of cells with fms constructs
The retroviral construct vsn2c-fms contains the complete
cDNA for the human M-CSFr, whereas vsn2v-fms carries an
oncogenic derivative, and was made previously (Dibb et al.,
1990). Retroviral construct vsn2c-fmsK612A was prepared
here and is otherwise identical to vsn2c-fms except that the
lysine residue 612 of the M-CSFr (Coussens et al., 1986) was
changed to alanine by oligo-directed mutagenesis using the
oligonucleotide TGCTGTCCTGGCCGTGGCTGTGA. Ishi-
kawa cells were infected by the addition of supernatant from
the retroviral packaging cell line PA317 that was separately
transfected with each of the retroviral constructs vsn2; vsn2c-
fms; vsn2v-fms and vsn2c-fmsK612A, as previously described
(Baker et al., 1994). The recombinant retroviruses vsn2c-fms:
vsn2v-fms and vsn2c-fmsK612A had equivalent infection
frequencies of Ishikawa cells in the order of 102 _03 G418
resistant colonies per ml of retroviral supernatant. As
expected, the control retrovirus vsn2 had a high infection
frequency owing to its smaller size (Dibb et al., 1990). Cells
infected with each of the constructs were selected in
1 mg ml-' G418 (Gibco), resistant colonies pooled and then
expanded for experimentation. Growth experiments were
performed under serum-free conditions in DMEM/F12/ITS
and assessed either by measurement of cell number after
trypsinisation or by assaying DNA after solubilisation ofcells
in 0.2% SDS and incubation with 1 mg ml-' Hoechst 33258
in SSC (Labarca and Paigen, 1980).
Results
To establish that the M-CSF transcript is translated in
Ishikawa cells conditioned medium was assayed for
immunoreactive protein with a rabbit polyclonal anti-human
M-CSF antibody, as shown in Figure 1. This assay
demonstrated the presence of immunoreactive M-CSF in
Ishikawa cell conditioned medium when the cells had been
grown under basal serum-free conditions. No immunoreac-
tive material was detected in serum-free medium that had not
been exposed to Ishikawa cells (data not shown). The amount
of M-CSF detected under basal conditions was inversely
proportional to the density of cells (Figure 2), suggesting that
M-CSF production decreased as the cells reached confluence.
To establish whether the control of M-CSF production in
Ishikawa cells was similar to that reported in other systems
cells were treated with TNF-a and phorbol ester (TPA),
which increase the titre of M-CSF (Ralph et al., 1986;
Yamada et al., 1991). This resulted in an increase in
immunoreactive M-CSF present in conditioned medium
(Figure 1). Elevation of intracellular cAMP by incubation
of Ishikawa cells with 8-bromo cyclic AMP also resulted in
an increase in immunoreactive M-CSF (Figure 1).
The role of the M-CSFr in the growth of Ishikawa cells
was investigated by the expression of retroviral wild-type c-
fms, which potentially could enhance the response to M-CSF,
and by the introduction of a kinase inactive, mutant receptor,
K612A, which would be expected to inhibit the activity of the
endogenous M-CSFr. The construct vsn2c-fms encodes a
functional M-CSFr as evidenced by its activity in FDC-PI
cells and Rat-2 fibroblasts (Dibb et al., 1990; Baker et al.,
1994). Ishikawa cells infected with vsn2c-fms grew signifi-
cantly faster than control cells (Figure 3a). The only source
of M-CSF for receptor activation under these serum-free
conditions was that produced endogenously by the cells.
Under identical culture conditions, cells infected with the
loss-of-function construct c-fmsK612A demonstrated a
decrease in cell growth compared with control cells (Figure
3b).
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Figure 1 Ishikawa cell conditioned medium contains immuno-
reactive M-CSF. Serum-free media collected from Ishikawa cell
cultures treated for 24h with TNF-a (a), 8-bromocyclic AMP (8-
Br) (b) or phorbol 12-myristate 13-acetate (TPA) (c), at the
indicated concentrations, were analysed for immunoreactive M-
CSF. Densitometry indicated that induction by each treatment
was in the range: TNF, 700-900%; 8-Br, 200-350%; TPA 350-
400%.
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Figure 2 M-CSF immunoreactivity is inversely proportional to
cell density. Ishikawa cells were plated at increasing concentra-
tions in serum-containing medium and then changed to serum-
free conditions for 4 days to achieve the final cell density
indicated. Medium was analysed for M-CSF immunoreactivity at
the end of the culture period. Regression analysis of arbitrary
densitometric units vs cell density indicated a correlation
coefficient (r2) of 0.93 (P<0.001).
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1994). Mutational activation of c-Ki-ras (Sasaki et al., 1993,
and references therein) and mutations in p53 (Inoue et al.,
1994, and references therein) have been reported in this
disease, but only in approximately one-third of cases. In
contrast, the majority of endometrial cancers overexpress c-
fims (Kacinski et al., 1988, 1990; Baiocchi et al., 1990;
Leiserowitz et al., 1993), and this expression is associated
with clinicopathological features of aggressive disease
(Kacinski et al., 1988; Leiserowitz et al., 1993).
In most primary sites of endometrial cancer and in all
metastatic lesions (Kacinski et al., 1990; Baiocchi et al.,
1991), c-fms and M-CSF were co-expressed. In comparison
with the low-level expression of c-fims and M-CSF in normal
endometrium observed in each of the above studies, this
suggests that abberant activation of the M-CSF/receptor
signalling pathway may contribute to endometrial carcino-
genesis. Data obtained in NIH-3T3 cells in which the
enforced expression of c-fims and M-CSF resulted in
transformation (Rettenmeier et al., 1987) supports this
hypothesis. We have previously demonstrated that Ishikawa
cells express M-CSF and c-fims mRNA and are responsive to
recombinant human M-CSF when grown under serum-free
conditions (Croxtall et al., 1992). The increase in growth of
Ishikawa cells following retroviral infection with a c-fms
construct (Figure 3a) suggests that activation of the M-CSFr
and of its signalling intermediates is associated with
proliferation in these cells. Activation of the M-CSFr is
Ishikawa cells
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Figure 3 Effect of wild-type and mutated c-fms on proliferation
of Ishikawa cells. Ishikawa cells infected with retroviral vsn2c-fins
construct (a) or vsn2fmsK612A (b), which is devoid of tyrosine
kinase activity, and selected in G418, were grown in serum-free
medium for the indicated number of days. Cultures were
harvested and growth determined by counting cell number, (a)
and (b), or additionally by measurement of DNA (a insert).
Values are presented for comparison with those obtained with
cells infected with vector alone (vsn2) and represent the mean and
s.d. of at least three determinations. (a), c-fms significantly greater
than control: day 6 P < 0.01, day 8, P < 0.05. (b) K612A
significantly less than control: day 6 P<0.05; day 8 P<0.01.
Infection ofIshikawa cells with vsn2c-fms resulted in a slight
increase in the kinase activity of the M-CSFr immunoprecipi-
tate compared with the activity of the endogenous M-CSFr
(Figure 4, compare lanes 1 and 2). In Ishikawa cells the
immature form of the M-CSFr predominated, regardless of
whether the cells had been infected with vsn2c-fms and
contrasted with the appearance of the mature and immature
forms ofM-CSFr in FDC-PI (Dexter et al., 1980) cells that had
been infected with vsn2c-fms, (Figure 4, lane 4). The failure to
detect the mature form of c-fms in Ishikawa cells is unlikely to
be due to a defect in the processing machinery of these cells
because we observed the mature form of the M-CSFr in cells
that overexpress the oncogene v-fms following infection with
vsn2v-fms (Figure 4, lane 3). Autophosphorylation ofM-CSFr,
owing to its intrinsic kinase activity, is a reliable indicator ofits
relative level ofexpression (Downing et al., 1989) and indicates
that in Ishikawa cells the introduction of vsn2c-fms did not
result in excessive expression.
Discussion
A relatively large number of chromosomal loci are likely to
play a role in the genesis of endometrial cancer (Fujino et al.,
*- M
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Figure 4 Measurement of fins expression by in v,itro kinase
activity. Cell lysates prepared from Ishikawa cells (lanes 1-3) and
FD cells (lane 4) were treated with polyclonal rabbit anti-human
c-fms antibody and the immunoprecipitates analysed for kinase
activity by incubation with [,y32P]ATP. Ishikawa cell lysates were
prepared from cells infected with vector alone (vsn2), vector
containing c-fims insert (vsn2c-fims) and vector containing v-fins
insert (vsn2v-fms). FDc-fins is the FDC-PI cell line infected with
vsn2c-fims. The mobilities of the mature and immature forms of
fims are indicated by the arrows labelled M and I respectively.
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associated with its internalisation and the disappearance of
the mature form of the receptor (Downing et al., 1989;
Sariban et al., 1989). The relatively low abundance of the
mature M-CSFr in Ishikawa cells (Figure 4) is therefore
consistent with its turnover as a result of M-CSF stimulation.
However, we have not as yet ruled out the alternative
possibility that the mature form of the M-CSFr is regulated
in these cells by the activity of protein kinase C, which is also
known to influence M-CSFr activity, but by a mechanism
independent of that stimulated by M-CSF (Downing et al.,
1989).
The ability of the loss-of-function mutant M-CSFr,
encoded by vsn2K612A, to retard the growth of Ishikawa
cells (Figure 3b) further strengthens the proposal that the
growth of Ishikawa cells is responsive to, but not dependent
upon, endogenously produced M-CSF. The mutant M-CSFr
presumably inhibits M-CSF-induced growth by forming
inactive heterodimers with the normal cellular M-CSFr.
However, the alternative possibility that homodimeric,
mutant, loss-of-function M-CSF receptors may act as a sink
for endogenous M-CSF also needs to be considered.
Regardless of the mechanism involved the data provide
evidence of the importance of activation of M-CSF signalling
pathways in the proliferation of endometrial cancer cells.
Detection of M-CSF in the conditioned medium of
Ishikawa cells, under conditions in which there is no other
source, indicates that the M-CSF transcript previously
detected in these cells (Croxtall et al., 1991) is translated
into protein. Regulation of M-CSF expression by TNF and
the phorbol ester, TPA, is consistent with such regulation in
monocytes (Ralph et al., 1986; Sherman et al., 1990; Yamada
et al., 1991). TNF regulation of M-CSF in HL-60 cells is the
result of transcriptional and post-transcriptional mechanisms,
in which cAMP is capable of antagonising the effects of TNF
(Sherman et al., 1990). Although cAMP was not used in
combination with TNF in the present study, its ability to
induce M-CSF suggests that it would be unlikely to
antagonise the effects of TNF in Ishikawa cells. Such
stimulation of M-CSF by cAMP is more typical of the
response observed in endothelial cells (Parhami et al., 1993).
These observations on the regulation of M-CSF in
endometrial cancer cells suggest the potential for locally
produced endometrial TNF and elevators of cellular cAMP
to influence the M-CSF/fms autocrine loop. At present the
molecular variants of the M-CSF transcripts in Ishikawa cells
have not been analysed and it remains to be determined
whether there is co-expression of species that encode secreted
and membrane-bround protein (Daiter et al., 1992).
Extrapolation of this data to the in vivo situation suggests
that there is a potential functional consequence to the co-
expression of M-CSF and c-fms in the majority of
endometrial carcinomas. Taken together with evidence of
the role of this loop in stimulating cellular invasion
(Filderman et al., 1992) it seems likely that deregulation of
M-CSF/c-fms expression and/or function has a pivotal role in
growth and metastasis of endometrial cancer. The ability of
interactive signalling pathways to regulate the expression of
M-CSF, as shown here (Figure 1), and the capacity of such
signalling pathways also to be involved in the regulation of c-
fms expression (Yue et al., 1993), provide avenues to explore
the molecular mechanism underlying such overexpression in
endometrial and ovarian cancer.
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